Fig. 1: Altered GASP1 in breast cancers and its association with patient survival. | Cell Death & Disease

Fig. 1: Altered GASP1 in breast cancers and its association with patient survival.

From: GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to paclitaxel by forming a vicious cycle with IGF1/IGF1R signaling pathway

Fig. 1

a Immunohistochemistry was performed to determine the level of GASP1 in breast cancers and normal breast tissues (n = 20). Scale bar, 200 µm. b GASP1 expression in different stages of breast cancer patients (data from TCGA database). c GASP1 expression in different breast cancer subgroups, including luminal, HER2 positive, and Triple-negative types (data from UALCAN platform). d A total of 5% (54/1084) of breast cancers exhibit GASP1 alterations (data from cBioPortal). e The frequency of GASP1 alterations in different pathological types of breast cancer, including mutation, genomic amplification, and high mRNA expression (data from cBioPortal). Numbers 1, 2, and 3 represent Invasive Mixed Mucinous Carcinoma, Invasive Lobular Carcinoma, and Invasive Carcinoma (NOS, respectively. f The association of GASP1 alterations with disease-specific survival and overall survival in breast cancer patients. Data were presented as mean ± SD. **P < 0.01; ***P < 0.001.

Back to article page